首页> 外文期刊>Therapeutic delivery >Interview with Paul Ashton: Sustained-release drug delivery to the eye
【24h】

Interview with Paul Ashton: Sustained-release drug delivery to the eye

机译:保罗·阿什顿(Paul Ashton)访谈:缓释药物输送到眼睛

获取原文
获取原文并翻译 | 示例
           

摘要

Paul Ashton is President and Chief Executive Officer of pSivida (MA, USA), a provider of miniaturized, sustained-release drug-delivery products with a primary focus in ophthalmology. He also served in this role at Controlled Delivery Systems, a company he co-founded in 1991. Prior to this, he was a joint faculty member at the University of Kentucky (KY, USA), faculty member at Tufts University (MA, USA) and pharmaceutical scientist at Hoffman-La-Roche (Basel, Switzerland). Dr Ashton spoke to Therapeutic Delivery about the progress and challenges of sustained-release drug delivery to the eye, both within and outside pSivida. Interview conducted by James Potticary, Assistant Commissioning Editor.
机译:Paul Ashton是pSivida(美国马萨诸塞州)的总裁兼首席执行官,该公司是一家小型,缓释药物递送产品的提供商,主要致力于眼科。他还曾在1991年与他人共同创立的公司Controlled Delivery Systems中担任过这一职务。在此之前,他是肯塔基大学(美国肯塔基州)的联合教员,塔夫茨大学(美国MA)的教员。 )和霍夫曼拉罗氏公司(瑞士巴塞尔)的药物科学家。 Ashton博士向Therapeutic Delivery讲述了在pSivida内部和外部向眼睛持续释放药物的进展和挑战。助理调试编辑James Potticary进行的采访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号